|
ZFP30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.60959999959832E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.89700000047455E-07 |
| Normal-vs-Stage2 |
8.48920000000586E-05 |
| Normal-vs-Stage3 |
3.41200000475439E-08 |
| Normal-vs-Stage4 |
2.49229999971234E-08 |
| Stage1-vs-Stage2 |
6.471000E-01 |
| Stage1-vs-Stage3 |
1.417000E-01 |
| Stage1-vs-Stage4 |
9.318500E-02 |
| Stage2-vs-Stage3 |
1.658170E-01 |
| Stage2-vs-Stage4 |
8.623900E-02 |
| Stage3-vs-Stage4 |
6.191600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.07509999581046E-08 |
| Normal-vs-AfricanAmerican |
1.597020E-03 |
| Normal-vs-Asian |
1.591150E-04 |
| Caucasian-vs-AfricanAmerican |
5.010200E-01 |
| Caucasian-vs-Asian |
1.176040E-01 |
| AfricanAmerican-vs-Asian |
6.620800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.69260000021576E-07 |
| Normal-vs-Female |
3.94119999969078E-08 |
| Male-vs-Female |
1.339040E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.11520000018106E-07 |
| Normal-vs-Age(41-60Yrs) |
2.29019999964386E-07 |
| Normal-vs-Age(61-80Yrs) |
1.0523000004703E-07 |
| Normal-vs-Age(81-100Yrs) |
2.108100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.966600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.316400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.586600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.193600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.771400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.594000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.038800E-04 |
| Classical-VS-Follicular |
5.202200E-01 |
| Classical-VS-Other |
9.125800E-01 |
| Classical-VS-Normal |
1.58329999999651E-06 |
| Tall-VS-Follicular |
1.493880E-02 |
| Tall-VS-Other |
3.473800E-01 |
| Tall-VS-Normal |
1.59689994561063E-09 |
| Follicular-VS-Other |
9.235800E-01 |
| Follicular-VS-Normal |
1.73469999997788E-06 |
| Other-VS-Normal |
4.728400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.7974000327855E-09 |
| Normal-vs-N1 |
1.33340000152415E-08 |
| N0-vs-N1 |
5.712000E-02 |
|
|
